{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:24:13Z","timestamp":1794857053707,"version":"4.9.1"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>There is an unmet need for novel medical therapies before recommending invasive therapies for patients with severely symptomatic obstructive hypertrophic cardiomyopathy (HCM). Mavacamten has been shown to improve left ventricular outflow tract (LVOT) gradient and symptoms and may thus reduce the short-term need for septal reduction therapy (SRT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine the cumulative longer-term effect of mavacamten on the need for SRT through week 56.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This was a double-blind, placebo-controlled, multicenter, randomized clinical trial with placebo crossover at 16 weeks, conducted from July 2020 to November 2022. Participants were recruited from 19 US HCM centers. Included in the trial were patients with obstructive HCM (New York Heart Association class III\/IV) referred for SRT. Study data were analyzed April to August 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Patients initially assigned to mavacamten at baseline continued the drug for 56 weeks, and patients taking placebo crossed over to mavacamten from week 16 to week 56 (40-week exposure). Dose titrations were performed using echocardiographic LVOT gradient and LV ejection fraction (LVEF) measurements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome and Measure<\/jats:title>\n                    <jats:p>Proportion of patients undergoing SRT, remaining guideline eligible or unevaluable SRT status at week 56.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 112 patients with highly symptomatic obstructive HCM, 108 (mean [SD] age, 60.3 [12.5] years; 54 male [50.0%]) qualified for the week 56 evaluation. At week 56, 5 of 56 patients (8.9%) in the original mavacamten group (3 underwent SRT, 1 was SRT eligible, and 1 was not SRT evaluable) and 10 of 52 patients (19.2%) in the placebo crossover group (3 underwent SRT, 4 were SRT eligible, and 3 were not SRT evaluable) met the composite end point. A total of 96 of 108 patients (89%) continued mavacamten long term. Between the mavacamten and placebo-to-mavacamten groups, respectively, after 56 weeks, there was a sustained reduction in resting (mean difference, \u221234.0 mm Hg; 95% CI, \u221243.5 to \u221224.5 mm Hg and \u221233.2 mm Hg; 95% CI, \u221241.9 to \u221224.5 mm Hg) and Valsalva (mean difference, \u221245.6 mm Hg; 95% CI, \u221256.5 to \u221234.6 mm Hg and \u221254.6 mm Hg; 95% CI, \u221266.0 to \u221243.3 mm Hg) LVOT gradients. Similarly, there was an improvement in NYHA class of 1 or higher in 51 of 55 patients (93%) in the original mavacamten group and in 37 of 51 patients (73%) in the placebo crossover group. Overall, 12 of 108 patients (11.1%; 95% CI, 5.87%-18.60%), which represents 7 of 56 patients (12.5%) in the original mavacamten group and 5 of 52 patients (9.6%) in the placebo crossover group, had an LVEF less than 50% (2 with LVEF \u226430%, one of whom died), and 9 of 12 patients (75%) continued treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Results of this randomized clinical trial showed that in patients with symptomatic obstructive HCM, mavacamten reduced the need for SRT at week 56, with sustained improvements in LVOT gradients and symptoms. Although this represents a useful therapeutic option, given the potential risk of LV systolic dysfunction, there is a continued need for close monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04349072\">NCT04349072<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2023.3342","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T11:32:46Z","timestamp":1693222366000},"page":"968","source":"Crossref","is-referenced-by-count":180,"title":["Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction"],"prefix":"10.1001","volume":"8","author":[{"given":"Milind Y.","family":"Desai","sequence":"first","affiliation":[{"name":"The Hypertrophic Cardiomyopathy Center, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio"},{"name":"Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio"},{"name":"Coordinating Center for Clinical Research Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Owens","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Wolski","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio"},{"name":"Coordinating Center for Clinical Research Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Geske","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Saberi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sherrid","sequence":"additional","affiliation":[{"name":"Department of Cardiology, New York University, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Cremer","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio"},{"name":"Coordinating Center for Clinical Research Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal K.","family":"Lakdawala","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albree","family":"Tower-Rader","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fermin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Corewell Health, Grand Rapids, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srihari S.","family":"Naidu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center, Valhalla, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Smedira","sequence":"additional","affiliation":[{"name":"The Hypertrophic Cardiomyopathy Center, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio"},{"name":"Department of Cardiothoracic Surgery, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartzell","family":"Schaff","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"McErlean","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio"},{"name":"Coordinating Center for Clinical Research Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Sewell","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio"},{"name":"Coordinating Center for Clinical Research Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Mudarris","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqun","family":"Gong","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Lampl","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Sehnert","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio"},{"name":"Coordinating Center for Clinical Research Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"hoi230047r1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study\u2014Coronary Artery Risk Development in (Young) Adults.","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"issue":"12","key":"hoi230047r2","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy.","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"39","key":"hoi230047r3","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC).","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"issue":"25","key":"hoi230047r4","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines.","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hoi230047r5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of hypertrophic cardiomyopathy: JACC state-of-the-art review.","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"hoi230047r6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2005.02.090","article-title":"Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy.","volume":"46","author":"Ommen","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi230047r7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.athoracsur.2007.07.063","article-title":"Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy.","volume":"85","author":"Smedira","year":"2008","journal-title":"Ann Thorac Surg"},{"issue":"16","key":"hoi230047r8","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1161\/01.CIR.0000162460.36735.71","article-title":"Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy.","volume":"111","author":"Woo","year":"2005","journal-title":"Circulation"},{"issue":"22","key":"hoi230047r9","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/j.jacc.2011.08.040","article-title":"Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment.","volume":"58","author":"Ball","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"hoi230047r10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1161\/CIRCULATIONAHA.112.000849","article-title":"Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction.","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"hoi230047r11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016210","article-title":"Outcomes in guideline-based class I indication vs earlier referral for surgical myectomy in hypertrophic obstructive cardiomyopathy.","volume":"10","author":"Alashi","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"hoi230047r12","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1016\/j.athoracsur.2020.09.011","article-title":"Late health status of patients undergoing myectomy for obstructive hypertrophic cardiomyopathy.","volume":"111","author":"Nguyen","year":"2021","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"hoi230047r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.7293","article-title":"Association of septal myectomy with quality of life in patients with left ventricular outflow tract obstruction from hypertrophic cardiomyopathy.","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"30","key":"hoi230047r14","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1093\/eurheartj\/eht495","article-title":"Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population.","volume":"35","author":"Veselka","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"hoi230047r15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/ccd.v84.1","article-title":"Early outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a European multicenter and multinational study.","volume":"84","author":"Veselka","year":"2014","journal-title":"Catheter Cardiovasc Interv"},{"issue":"20","key":"hoi230047r16","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.111.076257","article-title":"Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy.","volume":"126","author":"Sorajja","year":"2012","journal-title":"Circulation"},{"issue":"12","key":"hoi230047r17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168407","article-title":"A small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy.","volume":"11","author":"Stern","year":"2016","journal-title":"PLoS One"},{"issue":"10253","key":"hoi230047r18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"hoi230047r19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial.","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"issue":"2","key":"hoi230047r20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"hoi230047r21","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","article-title":"Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: outcomes through 32 weeks.","volume":"147","author":"Desai","year":"2023","journal-title":"Circulation"},{"key":"hoi230047r22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ahj.2021.05.007","article-title":"Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.","volume":"239","author":"Desai","year":"2021","journal-title":"Am Heart J"},{"issue":"25","key":"hoi230047r23","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1016\/j.jacc.2011.06.011","article-title":"2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines\u2014developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.","volume":"58","author":"Gersh","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"hoi230047r24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.122.014986","article-title":"Myosin inhibition and left ventricular diastolic function in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: insights from the VALOR-HCM Study.","volume":"15","author":"Cremer","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"issue":"4","key":"hoi230047r25","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","article-title":"Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review.","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi230047r26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2174\/1573403X1201160126125403","article-title":"Drug therapy for hypertrophic cardiomypathy: physiology and practice.","volume":"12","author":"Sherrid","year":"2016","journal-title":"Curr Cardiol Rev"},{"issue":"16","key":"hoi230047r27","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.jacc.2022.02.024","article-title":"Effects of metoprolol on exercise hemodynamics in patients with obstructive hypertrophic cardiomyopathy.","volume":"79","author":"Dybro","year":"2022","journal-title":"J Am Coll Cardiol"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2809050\/jamacardiology_desai_2023_oi_230047_1695753697.45465.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T11:13:04Z","timestamp":1697022784000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2809050"}},"subtitle":["Week 56 Results From the VALOR-HCM Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.3342","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,1]]}}}